Immunohematotoxicity studies with combinations of dapsone and zidovudine.
We investigated the immunohematoxicities of the antiparasitic drug dapsone (DDS) and the antiretroviral drug zidovudine (ZDV, AZT) given alone or in combination in BALB/c mice. DDS is used for prophylaxis and treatment of Pneumocystis carinii infection in AIDS patients. We examined the impact of concurrent administration of these drugs on the immune and hematopoietic systems because DDS causes hematotoxicity and ZDV therapy results in bone marrow toxicity. Daily oral administration of DDS at 25 and 50 mg/kg for 28 days caused a slight anemia, marked methemoglobinemia, reticulocytosis, and a moderate leukopenia (P < 0.01 for all parameters) but had no discernible effect on platelet count. In DDS-treated mice, the proliferative response of splenic T cells to concanavalin A was > or = 35% higher than that manifested by splenocytes from vehicle-treated control mice. ZDV at 240 and 480 mg/kg was not immunosuppressive but caused low-grade macrocytic anemia, thrombocytosis, and neutropenia; these effects were drug dose-dependent and statistically significant (P < 0.01). Concurrent administration of DDS and ZDV augmented the severity of ZDV-mediated macrocytic anemia, and 7 of 12 (58%) mice did not survive treatment with the high doses of DDS and ZDV (50 and 480 mg/kg, respectively). On the other hand, co-administration of ZDV mitigated DDS-induced methemoglobinemia and the DDS-associated elevation in lymphoproliferative response. These data suggest interaction between DDS and ZDV in mice and indicate a need for caution in using DDS as long-term therapy in AIDS patients receiving ZDV.
Freund
Y R
YR
SRI International, Menlo Park, CA 94025-3493, USA. yvonnerfreund@aol.com
Dousman
L
L
Riccio
E S
ES
Sato
B
B
MacGregor
J T
JT
Mohagheghpour
N
N
D017088:AIDS-Related Opportunistic Infections / Q000517:prevention & control; D000740:Anemia / Q000139:chemically induced*; D000818:Animals; D019380:Anti-HIV Agents / Q000008:administration & dosage / Q000633:toxicity*; D000981:Antiprotozoal Agents / Q000008:administration & dosage / Q000633:toxicity*; D001853:Bone Marrow / Q000187:drug effects; D003208:Concanavalin A / Q000494:pharmacology; D003622:Dapsone / Q000008:administration & dosage / Q000031:analogs & derivatives* / Q000097:blood / Q000633:toxicity*; D004305:Dose-Response Relationship, Drug; D004347:Drug Interactions; D005260:Female; D007970:Leukopenia / Q000139:chemically induced*; D008198:Lymph Nodes / Q000187:drug effects; D008213:Lymphocyte Activation / Q000187:drug effects; D008708:Methemoglobinemia / Q000139:chemically induced*; D051379:Mice; D008807:Mice, Inbred BALB C; D009503:Neutropenia / Q000139:chemically induced; D011020:Pneumonia, Pneumocystis / Q000517:prevention & control; D013922:Thrombocytosis / Q000139:chemically induced*; D013950:Thymus Gland / Q000187:drug effects; D015215:Zidovudine / Q000008:administration & dosage / Q000633:toxicity*
D019380:Anti-HIV Agents; D000981:Antiprotozoal Agents; D003208:Concanavalin A; D015215:Zidovudine; D003622:Dapsone; C018965:monoacetyldapsone